Overview

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Status:
Active, not recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab. Trastuzumab (also called Herceptin) is an antibody that attacks HER2 protein in tumor cells. Bevacizumab (also called Avastin) works by slowing or stopping the growth of cells in cancer tumors by decreasing the blood supply of the tumors. If blood supply is decreased, oxygen and nutrients that are needed for tumor growth are decreased. The chemotherapy used in this trial is called CAPOX, which is an abbreviation of capecitabine and oxaliplatin.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Brigham and Women's Hospital
Genentech, Inc.
Massachusetts General Hospital

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin
Trastuzumab